Therapeutic Targeting of the Cancer-Specific Cell Surface Biomarker nfP2X7

Julian A Barden1*, Angus Gidley-Baird1, Liew Cheng Teh1, G-Halli Rajasekariah1, John Pedersen2, Neil I Christensen2, Derek Spelman4 and David M Ashley4

1 Biosceptre (Aust) Pty Ltd, Riverside Life Sciences, 11 Julius Ave, North Ryde, N.S.W. 2113, Australia
2TissuPath, 165 Burwood Rd, Hawthorn, Vic 3122, Australia
3 School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA
4 Department of Veterinary Pathology, the University of Sydney, N.S.W. 2006, Australia
5 Deakin University, School of Medicine, Geelong, Vic, 3217, Australia

Abstract

The degree of unmet need for new therapeutics in oncology is clear since about 30% of the population die from cancer with enormous associated costs in health care and in personal impact. New and preferably specific targets are needed now to address the problem, both to improve overall survival and importantly to reduce side effects in order to improve quality of life. nfP2X7 is a receptor that, unlike P2X7, cannot enable apoptosis in cancer cells. Having established the widespread coverage of human cancers in which the aberrant receptor is found, attention has been drawn to the therapeutic potential of the target and whether an immunotherapeutic approach is capable of providing a significant therapeutic response. We demonstrate the intrinsic target specificity, the delivery of antibody within target cells, the extremely good safety profile of the targeting antibody and the broad range of cancer tissue that could be treated in both humans and other animals.

Keywords: nfP2X7 receptor; Oncology; Immunotherapy; Antibody; Cancer; Immunohistology

Introduction

P2X receptors form ATP-gated cation-selective channels on the plasma membrane of cells in a range of tissues such as smooth muscle and nerves [1-4]. P2X7, is one such member of this ionotropic purinergic receptor family. The P2X7 subtype mediates cell death, particularly in haematopoietic and immune cells including thymocytes [5], dendritic cells [6], lymphocytes [7,8], macrophages [9] and monocytes [10] and and is critically important for phagocytosis [11-13]. The receptor is also present in other cell lineages at some stage of the cell cycle. These include epithelial, mesenchymal and neural cell types [14-17]. P2X receptors exhibit two homologous transmembrane domains separating a similar sized extracellular domain from intracellular domains of variable size. These transmembrane segments show the most homology across P2X subtypes. P2X7, has a short N-terminal intracellular segment and, unlike other P2X subtypes, a long intracellular C-terminal domain [18]. The C-terminal domain is critical for supplying the measured pore-forming properties of the homotrimeric membrane channel [19-20]. Prolonged exposure of the assembled channel to ATP in which all three sites are occupied close to the neighbouring residues K193 and K311 juxtaposed from adjacent monomers, found critical for function [21], results in additional pore dilation [20,22,23]. Saturation ATP binding to the three binding sites formed by the correct packing of the monomers in the trimer results in a rapid increase in the influx of calcium that results in turn in the activation of caspases [24], leading to apoptosis of the affected cell [25].

However, the P2X7 receptors expressed on the surface of the cancer cells are unable to induce apoptosis [26,27]. These receptors continue to function as calcium channels due to the continued integrity of one of the ATP binding sites but lack the ability to form dilated pores [28]. They are identified as non-functional for pore formation and called nfP2X7 [27]. Since the receptors have ATP binding sites formed only by the correct packing of the monomers, the residual calcium current induced by ATP binding suggests that at least two of the monomers are correctly packed in order to form a single ATP binding site. A single incorrectly packed monomer could therefore disrupt two of the ATP binding sites [27]. The disruption at these sites would prevent pore formation and consequent apoptosis. Incorrect packing of a monomer in the trimer may arise from a minor disruption in interactions with one or more of the eleven intracellular accessory binding proteins needed to anchor P2X7, in the plasma membrane. Alternative mechanisms for disruption of the ATP binding sites may involve the insertion of a splice isoform or monomer with a single nucleotide polymorphism into the P2X7, trimer [29,30]. Irrespective of the mechanism or mechanisms giving rise to the exposure of epitopes such as part of 200-216 in the pair of ATP binding domains that become exposed in nfP2X7, conformers, a pair of selective targets is presented that is unavailable on P2X7, [26,27]. Selective targeting of an otherwise hidden pair of epitopes on the receptor surface allows for exquisite discrimination between any normal cells that may express fully functional P2X7, and transformed cells that express non-functional receptors.

Most normal human tissues including skin [14], breast [15] and prostate [16] appear largely devoid of P2X7, receptors until the onset of cancer [27]. Cancer tissues from a wide range of human and other animal sources demonstrate significant levels of surface nfP2X7, receptor expression [27]. The nfP2X7, membrane current drives proliferation [28] and morphological change through shedding of anchorage proteins leading to cells showing the highest aberrant nfP2X7, receptor-induced current becoming the cells with the highest invasion potential [27].

While surface residues on the P2X7, protein vary widely between species, the small and specific target epitope exposed in nfP2X7, is highly conserved. Thus, antibodies designed to detect nfP2X7, in human tissue have the potential to detect any such aberrant receptor in other species. The binding constant of ATP for P2X7, is relatively high, 0.1 mM.

*Corresponding author: Julian A Barden, Biosceptre (Aust) Pty Ltd, Riverside Life Sciences, 11 Julius Ave, North Ryde, N.S.W. 2113, Australia, Tel: 124908280 ; E-mail: julian.barden@biosceptre.com

Received: May 27, 2016; Accepted: June 13, 2016; Published: June 21, 2016


Copyright: © 2016 Barden JA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
[26]. A slight variant fold at the monomer-monomer interfaces that is assembled between the single incorrectly folded or packed monomer and the pair of adjacent correctly packed monomers would result in loss of ATP binding at these two altered sites. Any mutation in these critical residues is likely to disrupt ATP binding. ATP would either bind more weakly, and therefore effectively not at all, resulting in loss of function or else would bind more strongly, leading to an accidental prolonged receptor activation resulting in unwanted cell death. The absence of mutations in the critical epitope underlying the ATP binding site across species is singularly indicative of its importance to receptor structure-function [27]. Antibodies to such a conserved target in humans, exposed only when cells are attempting to initiate apoptosis, could therefore be used to test for both safety and efficacy in a wide range of species used in the drug development process, greatly reducing risks from off-target side effects. The presence of a high density of fully functional P2X receptors on leukocytes makes specific targeting of this receptor especially important in order to avoid neutropaenia.

Here we examine the specific binding of affinity purified polyclonal antibodies to cancer tissue and the therapeutic potential of the nP2X receptor.

Methods

Specimens

Prostate biopsy tissues and the marsupial Tasmanian Devil tumour tissue samples and cat tissue samples were supplied from the laboratories of contributing authors JP, DS and NC, respectively.

Tissue labelling

Biopsy tissues were processed in order to carefully ensure thorough, but not over fixation, with standard paraffin embedding. Paraffin sections were cut to approximately 5 µm and placed on coated slides that were usually stained within 2-3 days of being prepared as described [27].

Antibody preparation

Sheep were immunised against the nP2X target epitope 200-216 [26]. Target specific IgG antibody was affinity purified on an Affigel-10 column with elution controlled by an Akta Explorer. The antibody was labelled with FITC (Pierce 50327) for direct microscopy.

Cell preparation

PC3, COLO205, 4T1, B16 and HEK293 cells were supplied by ATCC. PC3, COLO205 and 4T1 cells were cultured in standard RPMI complete medium. A 500 mL bottle of RPMI-1640 (GibcoBRL 11875-093) had the following constituents added; 5.0 mL 1 M HEPES solution (Sigma G-1146), 0.5 mL 2-Mercaptoethanol solution (50 mM), 5.0 mL Penicillin (10,000 U)-Streptomycin (10 mg)-L-Glutamine (200 mM) (pH 7.0), 5.0 mL Sodium Pyruvate (100 mM, Sigma S-8636), 5.0 mL Phenol Red (50 mM) solution (Sigma P-6079). 0.5 mL 2-Mercaptoethanol solution (50 mM), 50 mL heat inactivated (40 min at 56°C) Foetal Calf Serum (HyClone 10010-056) was aspirated and the cells were centrifuged at 500 x g at 25°C and supernatant discarded and the process repeated. Cells were counted using a haemocytometer. Cells were grown to 70-90% confluency in T75 flasks. The supernatant was aspirated and the cells washed twice with buffer and aspirated. Cell dissociation buffer (2 mL) was added for 20 min at 37°C and the cells dislodged by gentle tapping of the flask. Primary or secondary antibodies were aliquoted into the flow tubes in readiness for the addition of the cells. Cells were resuspended in a 50 mL Falcon tube with buffer added to 50 mL. Cells were centrifuged at 1000 x g at 25°C and supernatant discarded and the process repeated. Cells were counted using a haemocytometer. Cell pellet was resuspended in HBSS (Gibco 21250-022) with 2% FCS to 1.5 x 10⁷ cells/mL. Each flow run on the Beckman Coulter Quanta SC used up to 100 µL of cell suspension. Specific and control antibodies were added to appropriate tubes and cells incubated for 20 min at 4°C. The secondary antibody (Southern Biotech SB601002 rabbit F(ab)2 anti-sheep IgG(H+L)-FITC) was used at 1:25 for 20 min. at 4°C in the dark. The cells were washed with 1 x HBSS and 2% FCS, the cells were centrifuged at 200 x g for 5 min at 4°C and supernatant aspirated prior to pellet resuspension in the same buffer to which was added 1 ul of 7AAD (Beckman Coulter 13422) in order to identify dead cells so these could be excluded from analysis.

Results

Species cross-reactivity

The appearance of novel and ubiquitous nP2X receptors at the onset of human and other mammalian cancers indicates that the antibody probe can be used as an important adjunct to current diagnoses of cancer. Evidence for the broad appearance of nP2X receptors in human cancers has been shown [27]. The reagent developed for the formalin fixed and paraffin embedded (FFPE) human tissue sections can be used to detect receptor expression in tumour sections from other species. An example of a tumour arising in a non-human is shown in the form of sections from the Tasmanian Devil, a marsupial that is suffering from Devil Facial Tumour Disease (DFTD) transmitted between animals as a result of transfer of a small number of clonal cancer cells from bites when fighting. A section of the primary was stained for nP2X. The edge of the tumour on the skin surface is shown in Figure 1a. Figure 1b reveals a clear cytoplasmic and membrane distribution on affected cells supported by normal stroma in the deeper transformed zone of the primary tumour. Metastatic cells appear in the lung. These too are clearly stained for nP2X (Figure 1c). Similar patterns are seen in mice, possums and domestic animals such as cats and dogs.

Increase in nP2X receptor expression with tumour grade

There are indications that the nP2X receptor expression varies with tumour grade, at least in prostate cancer, providing the potential to differentiate between latent and aggressive forms of cancer. Tissue biopsies taken from men with confirmed cancers graded for Gleason score or confirmed normal by repeat negative biopsies over time were stained for nP2X receptor. Sections of FFPE tissue taken from patients...
sections of still normal morphology adjacent to higher grade tumours i.e. those tumours that had transformed from being well-differentiated to moderately or poorly differentiated was more likely to be stronger and showed a characteristic pattern in which the basement membrane became heavily stained (Figure 2e). This pattern appeared prior to stromal invasion in the stained sections. The pattern was continued in the tumour sections (Figure 2f) in which stromal invasion was apparent and often where higher grade tumour had appeared in the apical epithelium. Stromal stain was a strong feature and indicative of shed receptor displaced from the adjacent affected apical epithelium as such stain was absent further from the tumour centre.

**In vitro binding to live cells**

Affinity purified sheep anti-nfP2X, antibody was tested for specific binding to the target conformational epitope by generating the P2X extracellular domain (ECD) recombinantly and by transfecting it into HEK293 cells. Flow cytometry was used to measure binding to mock transfected (no DNA), empty transfected (no P2X, DNA) and those transfected with the extracellular domain monomers. Dose-dependent specific binding of the sheep anti-nfP2X, IgG antibody to the ECD on the cell surface was measured over the concentration range 4-128 nM (0.6-20 µg/mL). Binding to either mock or blank vector transfected cells was less than 2%, similar to the level recorded for secondary antibody conjugate alone (Figure 3).

Specific binding to nfP2X receptors was examined on a wide range of cancer cell types using flow cytometry. An example is shown using live COLO205 cells in Figure 4. The results of these studies using FITC-labelled sheep anti-nfP2X, indicated strong binding. Reproducible strong binding of the sheep anti-nfP2X, IgG to live tumour cells known to express nfP2X, from immunohistochemical studies on tumour cells in cytospins and fixed cancer tissue sections suggested the potential utility of the antibody for targeted killing of tumour cells, provided there was little or no cross-reactivity with P2X receptors on normal cells such as lymphocytes. Human B-lymphocytes were extracted from donor blood and the same sheep antibodies tested for binding. There was no detectable shift in the mean fluorescence intensity with either control or specific anti-nfP2X antibody above the signal detected for samples containing cells only thus indicating no cross-reactivity with wild type functional receptor.

**Endocytosis of sheep anti-nfP2X, antibody in PC3 cells**

PC3 cells were grown on coverslips and preincubated on ice with 100 nM FITC conjugated affinity purified sheep anti-nfP2X, IgG antibody for 30 minutes and then washed with PBS. Coverslips were fixed immediately (Figure 5a) or incubated in normal media at 37°C for 30 minutes (Figure 5b) or 2 hours (Figure 5c) before fixation. Cells were counterstained with Hoescht and imaged by confocal microscopy. After preincubation (Figure 5a) only surface binding of sheep anti-nfP2X, is seen, upon incubation at 37°C antibody rapidly internalises after 30 minutes (Figure 5b) and accumulates in intracellular compartments after 2 hours (Figure 5c).

**In vitro tumour cell killing**

Studies were undertaken to observe direct cell killing effects of the affinity purified sheep anti-nfP2X, IgG antibody either alone or in combination with standard cytotoxic drugs.

Human D270 malignant glioma cells are resistant to low levels of cisplatin. These were tested to determine whether there was augmented cell killing in the presence of the sheep anti-P2X, IgG antibody. Cells were
incubated at 37°C in the presence of a 15 uM sub-lethal concentration of cisplatin and sheep anti-nfP2X7 IgG antibody in concentrations ranging up to 24 nM for 24 h. Control wells were treated with the same concentrations of control sheep IgG and cell death measured by Cell Titer Blue assay. The background percentage of dead cells in the control wells was 15%. Specific antibody concentrations above 6 nM resulted in increased cell death (Figure 6). At 24 nM the specific antibody increased cell killing to 47% compared with 23% with the control, a concentration that is readily attainable in serum by intravenous injection.

**In vivo efficacy in mouse xenograft tumour models**

A model of the inhibition of growth and spread of metastases was established in Balb/C mice inoculated with the 4T1 breast tumour cells. Groups of 8 mice were randomly assigned after inoculation into those treated with control buffer injections and those treated with the sheep anti-nfP2X7 IgG antibody at 10 mg/kg in 2 mM citrate buffer. Injections via tail vein occurred on Days 0, 2, 4, 6, 9 and 12. Animals were sacrificed on Day 14 and the tissues examined for lung metastases. The results are shown in Figure 7. An average of 8.1 metastases were present in the control mice while there was an average of only 3.1 per mouse in the treatment group. Results were significant at P<0.001 with t-test.

The aggressive B16 intradermal mouse melanoma model was
used to measure the effect of a topical application of sheep anti-nfP2X<sub>7</sub>, antibody or non-specific control sheep IgG on in vivo tumour growth inhibition. In this study female black hairless C57/BL6 mice were injected intradermally with B16 melanoma cells and randomly allocated to groups that were untreated controls or treated with a topical ointment containing 7 mg anti-nfP2X<sub>7</sub>, antibody/g ointment base. Treatments were applied on days 5, 9, 13 and 16. Tumour sizes were measured on day 5 after injection and subsequently every two days thereafter until day 19 at which time mice were killed. The results are shown in Figure 8. A statistically significant reduction in tumour growth is evident (P<0.0001) from the date of the second treatment i.e. within 4 days of the initial application of the antibody.

**In vivo efficacy in a cat with untreated SCC of the nose**

Approval was sought by a specialist veterinary oncology group to test the antibody on a cat presenting with an otherwise advanced
squamous cell carcinoma originating in the left nostril but invading throughout the nasal cavity (bilateral) and extending to the top of the left orbit and across each maxilla. Surgery was declined due to the invasiveness of the procedure and the low likelihood of complete excision. A biopsy was taken from the left nostril and stained for target receptor. Figure 9 shows that just like human cancer tissue and marsupial cancer tissue, feline SCC stained strongly and specifically for nP2X7. The surrounding normal tissue is completely devoid of target receptor and there is no cross-reactivity. Sterile antibody (dose 4 mg/kg or 20 mg for the 5 kg cat) was prepared for intravenous injection via a canula in the left cephalic vein and the solution diluted in sterile saline at 1.6 mg/mL and administered via a pump over 1 h. The patient tolerated the foreign antibody very well. Bloods were collected and no anomalies detected. Figure 10a shows the patient at the start of treatment. The patient returned for treatment on Day 7 (Figure 10b). The lesion had formed an eschar and began lifting from the nasal bridge. The dose was increased to 6 mg/kg as the first dose was so well tolerated. On Day 14 (Figure 10c) another 30 mg (6 mg/kg) was administered. The nasal scabbing was markedly resolved and the lesion had become pink.
and alopecic. At Day 21 (Figure 10d), the benefits of the previous three doses were apparent. The lesion appeared completely resolved and new pink epithelialised tissue was present. Nevertheless, an additional 30 mg (6 mg/kg) treatment was administered on Day 21. An additional dose was administered a month later as a precaution against recurrence. The patient was re-examined with periodic follow-up over 2 years with no recurrence being detected. Blood samples were tested for the presence of anti-sheep antibody. By Week 4 the level of these antibodies was clear as demonstrated by ELISA.

Discussion

We previously showed that monoclonal antibodies developed for diagnostic detection of nP2X7 in FFPE human cancer tissues have shown high specificity across a wide range of human cancer types including but not limited to bowel, lung, breast, prostate, pancreatic, gastric, head and neck, skin, brain and Hodgkin’s lymphoma [27]. The target epitope underlies the ATP binding sites. These ATP sites only form when the P2X7 monomers are correctly packed in the assembled trimer inserted into the plasma membrane. These target binding sites for the specific antibody are sequence conserved across species as evidenced by the ability of the antibody developed against the human sequence to detect the exposed epitopes on nP2X7 receptors expressed on the surface of cancer cells from the marsupial Tasmanian Devil affected with facial tumour disease (Figure 1) both in the primary and in the metastatic cells spread to the lungs. The genotype and the karyotype of the cells extracted from FDTF tumours from different animals are consistent while being distinct from their hosts thus supporting the transmission of the disease between animals. This is a cancer of the Schwann cells that is rapidly depleting stocks of wild animals [31].

This conserved target indicates that the structure underlying and supporting the ATP site is critical to receptor function. While many differences have arisen in the sequence of the receptor between species, the target epitope has remained invariant. Any mutation that alters the ATP binding constant is potentially fatal given the low binding constant [26]. Such an invariant target exposed in receptors, unable to initiate the apoptotic signal on cells across many species, makes it ideal for development of specific therapeutics. Off-target binding of therapeutics developed in oncology give rise to unwanted side effects that can be costly through the need for increased doses to reach desired therapeutic concentrations and adverse effects on binding to non-cancer target tissue.

The nP2X7 receptor density appears to increase on the plasma membrane of affected cancer cells as their level of transformation increases. This is evident in prostate cancer tissue where normal tissue is seen to be devoid of receptor while well differentiated tumour tissue has only a moderate receptor density. As the tumour cells transform to moderately differentiated or poorly differentiated states, the density of receptors increases (Figure 2). Certainly, very slow growing low grade prostate cancers exhibit a pattern of receptor expression that is almost entirely intracellular, while cases of invasive prostate cancer exhibit more plasma membrane and basal cell labelling in advance of stromal invasion from the apical epithelium together with a significantly elevated cell surface receptor density [16,32,33].

The expression of P2X7 receptor is regulated by DNA methylation. In cervical cancer cells, the level of DNA methylation at the cis inhibitory element was reported to be higher than in normal cells [34]. In mammals, as both the DNA methyltransferases and a number of the histone methyltransferases play a role in the maintenance of DNA methylation [35-37], inhibition of these enzymes may be one mechanism by which an increased expression of P2X7 receptor occurs in cancers. Higher intratumoral expression has been found to be strongly correlated with poor patient outcome in clear-cell renal cell carcinoma [38]. Such mechanisms may facilitate the use of P2X7 receptor as a potential target for the novel immunotherapeutic approach of treating cancers.

Besides the up-regulation of P2X7 in prostate cancer observed by other groups [39], the receptor is expressed at high level in its non-functional form [15,40], an example of which involved the E496A mutant [41], a mutation found to produce a loss of pore functionality [42]. Additional confirmations, many very recently, of the up-regulation of the receptor in cancer tissue have been obtained for pancreatic [43], lung [44], skin [45-47], brain [48,49], renal [38], prostate [50], thyroid [51], bone [52] and both ALL and AML [53,54].

A previously developed monoclonal antibody raised against the same target was able to bind well to fixed tissue but was a poor binder against live cells. The affinity of the purified polyclonal antibody of type IgG raised in sheep was investigated for its ability to bind to the target expressed on live cells. Figures 3 and 4 show good specific binding of the antibody to both the expressed extracellular domain of the P2X7 monomer that presents the exposed epitope that is otherwise hidden in the correctly packed trimer on normal tissue as well as an example of the strong binding to the exposed epitope on the trimer of nP2X7, as expressed on cancer cells, COLO205 being just an example. The control antibody showed only trivial binding. Similarly, the specific antibody does not bind to the membrane surface of tissue that is normal, a result reinforced in testing of the antibody in a panel of normal and cancer tissue as part of the toxicity component for the FDA trial (NCT02587819) conducted as part of a topical therapeutic trial against BCCs. In contrast, with clear binding to nP2X7, receptors expressed on cancer cells, incubating the primary antibody with normal cells expressing equivalent density of P2X7, but in fully functional form, such as human B-lymphocytes, shows no binding.

Binding to target cancer cells was accompanied by cellular uptake (Figure 5). Short incubation times revealed punctate patches of surface receptor while longer exposure resulted in more widespread binding to surface receptors. Prolonged exposure to antibody for 30 minutes or more resulted in endocytosis of both receptor and bound antibody.

The therapeutic potential of the naked antibody was demonstrated in the associated cell killing assays, an example of which is shown in Figure 6 where the human glioma cancer cell line D270 was affected by specific antibody binding but not by the controls in 24 h. The xenograft 4T1 model of lung metastases in immunocompetent mice showed a statistically significant reduction in mean metastatic tumour number (Figure 7) at P<0.001. However, the inhibition of primary tumours implanted subcutaneously was much less effective. Examination of the antibody penetration in these tissues showed a lack of blood supply and consequent lack of penetration while the metastases were more accessible to the antibody (data not shown). Anti-antibody immune responses in these immunocompetent mice necessarily limits the time over which efficacy can be studied. A similar model in immunocompetent mice inoculated with the mouse B16 melanoma cell line showed that even topical applications were able to inhibit tumour growth by 50% over two weeks (Figure 8). In this situation, little or no immune reaction to the foreign antibody would act as a limit to duration of efficacy. An orthotopic tumour model or preferably a spontaneous tumour growth model in companion animals would provide more realistic settings to test nP2X7 antibody efficacy.
A treatment case study is presented of a cat that presented with a deeply invasive and extensive nasal SCC unable to be effectively treated with alternatives. The results obtained showed rapid lesion clearance via systemic delivery before the anti-sheep antibody response could render the treatment ineffective. No anaphylactic reaction was observed with the four infusions over 21 days that were all well tolerated. A final infusion administered a month later also had no adverse effects but the likelihood of this additional dose having been effective in the case of non-clearance would have been reduced due to the presence of anti-sheep antibodies. Importantly, complete clearance was obtained in the short available treatment window and no recurrence was seen over more than two years.

In a separate study, where hyperimmune sheep were used to produce cGMP anti-nfP2X, antibody, regular bleeds over several years showed no ill effects. There was no sign of neutropaenia even though lymphocytes have a high density of functional P2X receptor. These data support the specificity of the antibody for nfP2X receptor. Sheep organs examined after several years exposure showed no toxic effects of the treatment. Specificity for the epitope on cancer cells thus appears to be extremely high as the epitope is otherwise hidden in normal cells expressing fully functional P2X, with pore forming capability.

The monoclonal antibody [27] to nfP2X receptor appears highly specific and does not obviously bind on the surface of cells expressing only normal P2X receptor. This specificity augurs well for a human therapeutic lead that may well have clinical benefits across a wide range of cancer indications. The benefits are specific targeting, lower doses needed to target the tumour, and no unwanted side effects from off-target binding. That the target is highly conserved across species indicates that mutational drift in the target, as a result of therapeutic intervention, as is the case with easily mutable targets such as BCR-ABL, c-KIT and PDGFRA tyrosine kinases [53,54], is less likely to occur.

Acknowledgements

The authors wish to thank Drs. A. Kreiss and G. Woods from the Menzies Institute for Medical Research, University of Tasmania for original supply of Tasmanian devil facial tumour samples. JB, AGB and LCT note their continued Institute for Medical Research, University of Tasmania for original supply of c-KIT and PDGFRA tyrosine kinases [53,54], is less likely to occur.

References


